1.. Introduction
================

1.2.. Alzheimer's Disease (AD)
------------------------------

Alzheimer's disease (AD) is a devastating, continuous neurodegenerative disorder leading to neuronal loss and dysfunction of these cells. AD is the most frequent cause of dementia which constitutes 60%-70% of all dementia cases \[[@r1]-[@r3]\]. According to the World Alzheimer Report 2015, currently AD affects over 46 million people worldwide, which makes it one of the main health-care problem nowadays and the sixth-leading cause of death in the United States \[[@r4]\]. This number is expected to nearly double in the next 20 years, reaching almost 75 million in 2030 and over 130 million in 2050 \[[@r5]\]. AD is histopathologically characterized by the accumulation of intracellular neurofibrillary tangles (NFTs) consisted of many forms of phosphorylated Tau proteins (including pTau~181~) or truncated tau, localized mainly in neurons \[[@r6]\] and extracellular amyloid plaques consisted of amyloid beta (Aβ) throughout the brain \[[@r2]\]. It is estimated that all of these changes may start even 10-20 years before the onset of cognitive decline \[[@r7]\]. The development of pathological changes in the brains of AD patients could be examined convincingly only by the post-mortem identification or autopsy \[[@r8]\].

As reported by the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV-TR), the National Institute of Neurological Disorders and Stroke--Alzheimer Disease and Related Disorders (NINCDS--ADRDA) working group \[[@r9]\] and the 2011 recommendations from National Institute on Aging and the Alzheimer's Association (NIA-AA), AD is perceived as a disease continuum \[[@r10]\] and is considered to include three basic phases: preclinical (asymptomatic), mild cognitive impairment (MCI) and dementia due to AD \[[@r10]-[@r12]\]. Researchers assessed that progression rate from MCI to AD is about 10-20% yearly \[[@r13]\]. The main risk factors of AD are increasing age, low level of education \[[@r14]\] and vascular factors including smoking, obesity and diabetes \[[@r15]\]. Genetic changes also appear to have a significant impact on the risk of developing AD, with special attention to the presence of apolipoprotein E (APOE) ε4 genotype. In comparison to subjects without ε4 allele, the elevated risk for AD tends to be almost three-fold higher in people with one ε4 allele and twelve-fold higher in those who inherited two ε4 allele \[[@r16]\]. Moreover, the development of AD seems to occur in ε4 form carriers at younger age than in those with the presence of ε2 or ε3 allele of the *APOE* gene \[[@r17]\].

2.. Neuroimmflamation in AD
===========================

A growing body of evidence obtained from recent studies has proposed that the pathological process of AD is not only limited to the neuronal tissue, but also combines with immunological reactions in the brain \[[@r18]\] (Fig. **[1](#F1){ref-type="fig"}**). It is already known that brains of AD patients and other neurodegenerative diseases (NDs) are characterized by chronic inflammation \[[@r19], [@r20]\]. In AD brains, neuronal death and dysfunction together with the presence of insoluble Aβ deposits and NFTs, can trigger the process of inflammation \[[@r19]\], which stays in close connection with AD pathology and cognitive impairment \[[@r18]\]. Furthermore, the pathological aggregates of insoluble Aβ are recognized as foreign material and may cause the activation of the inflammatory reactions \[[@r21]\].

Cell mediators of inflammation in the AD brains are microglia and astrocytes, which are involved primarily in the inflammatory mechanisms ongoing in the brain \[[@r22]\]. Microglial cells are intensively activated cells \[[@r22]\], which gather during a chemotactic reaction within the senile plaques in the neocortex of AD patients. This phenomenon can be observed already in the early phase of the disease \[[@r23]-[@r25]\]. When activated by Aβ, these cells become the origin of inflammatory mediators, such as components of the complement system, inflammatory interleukins IL-1β and IL-6, tumor necrosis factor (TNFα), chemokines, macrophage inflammatory protein 1 (MIP-1), membrane-bound channel-activating serine protease 1 (mCAP-1), as well as free radicals \[[@r24], [@r26]\]. Moreover, in patients with AD, there is a significant cell loss in the locus coeruleus, a brain region responsible for the production of noradrenaline, which is also the endogenous anti-inflammatory agent \[[@r27]\]. In mice, this neurotransmitter stimulates microglial cells to suppress the production of cytokines induced by Aβ and to Aβ phagocytosis \[[@r27]\]. Various CSF inflammatory biomarkers \[[@r28]\], including soluble CD14, monocyte chemoattractant protein 1 (MCP-1), matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) \[[@r29]\] have been associated with microglial activation in neurological diseases.

It was shown that astrocytes act as immune sensing cells in the brain \[[@r30]\], and may also be implicated in the response to infection, injury and inflammation \[[@r31]\]. Astrocytes support neural transmission and improve the removal of nonessential synapses by trimming useless connections with the help of microglia \[[@r32]\]. Additionally, they are involved in the response to Aβ peptides and localize within close proximity to senile plaques \[[@r33]\]. Activated astrocytes may also release a variety of pro-inflammatory compounds, including interleukins, complement components, thromboxanes, coagulation factors, prostaglandins, leukotrienes, proteases and protease inhibitors \[[@r34]-[@r36]\]. Moreover, it has been demonstrated that neurons can also produce complement components, C-reactive protein (CRP), prostaglandins and cytokines (IL-1, IL-6, TNF-α) \[[@r19], [@r25]\].

The important role of neuroinflammation is supported by findings that genes for immune receptors, such as *TREM2*, a gene for triggering receptor expressed on myeloid cells 2 protein (TREM2), or *CD33*, encoding a transmembrane receptor CD33, expressed on cells of myeloid lineage, are associated with AD. The inflammatory response mediated by monocytes/macrophages can be stimulated through a variety of receptors, including TREM2 receptor. It was shown that homozygotic mutation in *TREM2* gene is associated with significantly increased risk of AD with early onset \[[@r37]\]. Furthermore, mutant rs3865444^C^ risk allele of *CD33* was associated with altered monocyte function and amyloid biology. *CD33* locus is one of the nine whole-genome loci associated with AD susceptibility. This implicates the immune system in AD predisposition. Moreover, the presence of this mutation was associated with increased cell surface expression of CD33 in the monocytes, increased numbers of activated human microglia and decreased internalization of Aβ~1-42~ peptide, accumulation of both neuritic amyloid plaques and fibrillar amyloid on *in vivo* imaging \[[@r38], [@r39]\].

Systemic inflammation is also believed as a factor influencing neuroinflammatory processes of the brain and then promoting AD progression \[[@r40]\]. Animal studies shown that the local inflammatory response to central and systemic endotoxins leads to increased neuronal death during chronic neurodegeneration \[[@r41]\]. The results of clinical studies of Alzheimer's disease revealed that cognitive decline was enhanced by acute and chronic systemic inflammatory diseases \[[@r42], [@r43]\]. Although priming of microglia is likely to

result from peripheral immune reaction, it might also be the response to chronic cerebrovascular dysregulation and microinfarcts within brain \[[@r44]\]. Moreover, these reactions are exaggerated in the ageing brain.

3.. Biomarkers of Alzheimer's disease
=====================================

Various hypotheses trying to explain the etiology of AD also highlight many biochemical indicators of the disease. It is believed that the sooner we are able to establish diagnosis of AD, the more benefits we will receive from the applied therapy (even if the current opportunities in this field are limited). The reliable diagnosis of AD is based on the detection of the presence of amyloid plaques and NFTs composed of pathological deposits of Tau protein in the neuronal tissue \[[@r45], [@r46]\]. The distribution of these deposits in the brain correlates with a stage of the disease \[[@r47]\]. However, the histopathological examination is not possible in patients' lifetime.

The diagnosis of living AD patients relies on the neuropsychological tests, imaging studies and biomarkers. There is sufficient evidence of the value of both AD CSF biomarkers as AD pathological correlates and the same with amyloid PET. Currently, AD biomarkers include Tau protein and its phosphorylated form pTau~181~ (indicators of neuronal injury), Aβ peptides (40 and 42) and the coefficient ratio Aβ~42/40~, the markers of amyloid precursor protein (APP) pathway, which are identified in the CSF \[[@r48]-[@r51]\], a biological material that requires invasive procedures to procure. Hence, looking for specific markers of AD, which could be determined in much more easily available biological materials, such as serum or plasma is urgent challenge in the diagnosis of this disease.

Although it is known that inflammation plays a significant role in AD pathogenesis \[[@r52]\], there is currently no inflammatory biomarker identified in body fluids as validated diagnostic method which would be useful to detect and/or monitor the course of the disease. Therefore, the modern and future research direction will focus also on the determination of inflammatory biomarkers in various body fluids, such as CSF and blood of AD patients \[[@r18]\]. Increasing knowledge about the neuroinflammation and regulation of the immunity mechanisms can pave the way towards the establishment of new therapies that may be useful to halt AD development or at least delay the onset of the cognitive decline \[[@r18]\].

In the last three decades, the concentrations of CSF inflammatory mediators in patients with AD and mild cognitive impairment (MCI) were determined \[for review see: 53\]. The reports suggest the possible role of elevated CSF levels of pro-inflammatory cytokines as risk factors for conversion of MCI to AD or as markers of the disease progression \[[@r54], [@r55]\]. In order to acquire the best possible explanation of the role of cytokines in AD, there is a growing need to obtain a satisfactory level of the method setting and patients' characteristics, along with the use of longitudinal studies \[[@r18]\].

4.. YKL-40- GENERAL CHARACTERISTICS
===================================

YKL-40, recognized as chitinase 3-like protein 1 (CHI3L1) or human cartilage glycoprotein 39 (HC-gp39) is a chitin-binding lectin which belongs to the glycosyl hydrolase family 18 \[[@r56],[@r57]\]. The name of YKL-40 was established based on its structure which consists of three N-terminal aminoacids: tyrosine (Y), lysine (K) and leucine (L) and the molecular mass of the protein is 40 kDa \[[@r58]\]. The amino acid sequence of human YKL-40 cDNA was described by Hakala *et al*. \[[@r59]\]. This protein consists of one polypeptide chain which includes 383 amino acids \[[@r59]\]. The construction of YKL-40 is based on two globular domains. The first one is a large domain composed of a (β/α)~8~ structure with the presence of a triose-phosphate isomerase (TIM) barrel fold, and the second one represents a small α/β domain consisted of five antiparallel β-strands and one α-helix that is settled in the loop between strand β7 and helix α7 of the TIM barrel. It results in complex grooved-shaped construction of YKL-40 molecule \[[@r58]\]. Isoelectric point of YKL-40 is approximately 7.6 \[[@r60]\].

*CHI3L1*, the human gene responsible for encoding YKL-40, was discovered in 1997 \[[@r61]\]. This gene is located in chromosome 1q31-q32 \[[@r56]\]. It has been shown that *CHI3L1* is composed of 10 exons with approximately 8 kilobases length of DNA data. There are two important mutations in the human YKL-40 gene. The first one involves the catalytic glutamic acid to leucine (L, residue 140) and the second is a mutation of the catalytic aspartic acid to alanine (A, residue 138). Presence of these mutations leads to deactivation of YKL-40 hydrolytic properties \[[@r62]\].

The expression of YKL-40 mRNA *in vitro* is highly intense in the course of human macrophage differentiation, especially in the final phase of this process. Furthermore, *in vivo* studies reported that expression of YKL-40 mRNA and protein is present in a various inflammation infiltrates and is involved in remodeling of extracellular matrix (ECM) \[[@r58]\]. YKL-40 protein is expressed by several types of cells including macrophages, chondrocytes, neutrophils and synovial fibroblasts \[[@r63]\]. Interestingly, there is no protein expression of YKL-40 in monocytes \[[@r56]\]. It has been indicated, that proinflammatory cytokines TNF-α and IL-1β induce the synthesis of YKL-40 in macrophages and chondro- cytes, especially in peripheral inflammatory conditions, such as arthritis and asthma \[[@r64], [@r65]\].

The mechanisms of the regulation of YKL-40 expression were also assessed in astrocytes *in vitro* \[[@r57]\]. It was shown that abundant expression of this protein was present in astrocytes in neuroinflammatory conditions as well as in cultured macrophages. In macrophages, the YKL-40 transcription was induced by classical activation pathway (M1) and inhibited by alternative activation (M2), whereas transcription of this protein in microglia *in vitro* was minimally changed by M1 or M2 activation \[[@r57]\]. Moreover, production of YKL-40 by macrophages increased as a function of time in *in vitro* culture \[[@r57]\]. The transcription of YKL-40 in astrocytes was induced by cytokines released from macrophages, resulting in morphological changes of astrocytes and their altered motility.

The physiological role of YKL-40 and its specific cell surface receptor are not known at this time. Although the protein is highly conserved in mammals, a consensus regarding its role in human pathologies is currently lacking. This protein was hypothesized to be involved in tissue remodeling during inflammation. In particular, it was indicated as a factor preventing the damage of extracellular matrix in response to proinflammatory cytokines, even though its biological function remains speculative. However, the physiological role of YKL-40 in brain tissue still remains unknown \[[@r52]\].

5.. The role of YKL-40 in AD
============================

In AD brains, the neuritic plaques consisting of fibrous deposits of the Aβ fragments of the amyloid precursor protein (APP) are surrounded by microglia. These cells play a role as the components of the immune response in the brain and express various pro-inflammatory cytokines at mRNA and protein level. Significantly increased expression of mRNA for chitinase-3 like 3 (CHI3L3), a mouse homologue of YKL-40, was found in brains of mice models of AD when compared to age-matched controls \[[@r66]\]. Similarly, in human brain samples, obtained in autopsy from individuals with pathologically confirmed AD, the levels of mRNAs for YKL-40 and chitinase-3 like 2 (CHI3L2), as well as mRNA for TNF-α, and were significantly increased in comparison with non-demented controls \[[@r66]\].

Despite the fact that there is no explanation which factors influence the expression of YKL-40 protein in the pathogenesis of AD, and how elevated expression level of YKL-40 can affect the process of the disease \[[@r52]\], it has been suggested, that YKL-40 might be a candidate for a biomarker of some chronic neuropathologies, including AD, which have an inflammatory background \[[@r67]\]. It can be assumed that astrocytic expression of YKL-40 might be activated by TNF-α and IL-1β, since it is known that these proinflammatory cytokines are involved in the process of neuroinflammation in AD pathology. Bearing in mind that these cytokines have an ability to pass the blood brain barrier (BBB), it can be also suspected that concentrations of YKL-40 in body fluids, such as CSF and plasma may be influenced by inflammatory processes ongoing in central nervous system or peripheral inflammation \[[@r52]\].

There are only few studies concerning concentrations of YKL-40 in cerebrospinal fluid of patients with full symptomatic AD and predementia stages as well as in other types of dementia (Table **[1](#T1){ref-type="table"}**). Recent studies have suggested the potential value of determination of YKL-40 CSF levels in the diagnosis of AD. In the paper by Rosén *et al*. \[[@r68]\], in AD patients CSF concentrations of YKL-40 were significantly elevated in comparison to cognitively normal individuals (77% increase), with the area under the curve (AUC) = 0.88. However, no correlations between the levels of YKL-40 and patients' age, mini-mental state examination (MMSE) or AD biomarkers have been found \[[@r68]\].

Increased concentrations of YKL-40 were observed not only in fully developed AD, but also in early stages of this disease. In the study of Antonell *et al*. the CSF concentrations of YKL-40 were significantly increased already in prodromal phase of AD when compared to cognitively normal controls \[[@r69]\]. Interestingly, the authors demonstrated a significant correlation between CSF YKL-40 and levels of Tau and pTau~181~, as well as with MMSE, opposite to the results of above mentioned study of Rosén *et al*. \[[@r68]\]. Similar observations were made in patients with preclinical AD \[[@r52]\], where CSF concentrations of YKL-40 were increased in very mild and mild dementia subjects in comparison with cognitively normal individuals. Moreover, the authors postulated that in evaluation of the risk of future cognitive decline, the prognostic value of ratio of YKL-40 to Aβ~1-42~ is similar to the ratio of Tau to Aβ~1-42~ \[[@r52]\]. The same authors revealed that astrocytes in close vicinity of amyloid plaques were immunoreactive to YKL-40, what confirms involvement of this protein in the neuroinflammatory response to Aβ deposition \[[@r52]\]. Results of more recent study of Kester *et al*. \[[@r70]\], concerning prognostic value of YKL-40 in AD are in line with these observations. CSF concentrations of YKL-40 in both AD and MCI patients were higher than in individuals without cognitive impairment. Additionally, baseline CSF levels of this biomarker were elevated in MCI patients who further progressed to AD in comparison with those MCI subjects who were clinically stable. Increased levels of YKL-40 predicted progression from MCI to symptomatic AD and other types of dementia as measured by annual assessment of MMSE within follow-up \[[@r70]\].

CSF concentrations of YKL-40 were also determined in middle-aged cognitively normal subjects with Clinical Dementia Rating (CDR) of 0 and compared with concentrations of AD biomarkers, such as Aβ~1-42~, Aβ~1-40~, Tau and pTau~181~ as well as with amyloid imaging in serial examinations within 6-year mean period of follow-up \[[@r71]\]. Additionally, APOΕ ε4 genotype was assessed in participants of the study to evaluate possible risk for further development of AD pathology. CSF levels of YKL-40 were significantly higher in older subject compared with younger participants of the study, both in ε4 group (180.3 ng/mL in early age, 231.3 ng/mL in mid age and 301.1 ng/mL in late age group) and in the ε4 non-carriers (188.4 ng/mL in early age, 240.6 ng/mL in mid age and 281.5 ng/mL in late age group). Within  the same age group, the concentrations of YKL-40 did not differ significantly between APOE groups, *i.e*., ε4 carriers and non-carriers. Moreover, concentration of this protein significantly increased within individuals over time, regardless age interval. The rate of the increase in YKL-40 concentration in the ε4 carriers was significantly higher in comparison with ε4 non-carriers. Elevation of YKL-40 CSF levels in all age intervals observed might be explained by the fact that neuroinflammation is a process ongoing normally with aging. However, the highest increases observed in ε4 carriers suggest that this process may be further intensified in the presence of neuronal damage and amyloid accumulation \[[@r71]\].

YKL-40 CSF levels in cognitively normal individuals were described by Alcolea *et al*. \[[@r72]\], who assessed it across the preclinical stages of the NIA-AA classification: stage 0, 1, 2, 3, and in patients with suspected non-Alzheimer pathology (SNAP). All participants had a Mini-Mental State Examination (MMSE) score at least 24 points and normal memory performance. The participants with preclinical stages of AD and those with SNAP showed different profiles of YKL-40 concentration in CSF. Significantly increased levels of YKL-40 were observed in cognitively normal patients with stages 2 and 3, as well as in patients with SNAP when compared to those in stages 0 and 1 \[[@r64]\]. Independently on APOE status, CSF levels of YKL-40 correlated positively with patients' age, similarly to concentrations of Tau and pTau~181~ in CSF, and with Tau regardless Aβ~1-42~ concentrations in CSF \[[@r72]\]. These observations suggest that the development of AD may be connected with the inflammatory response in the brains of ageing patients.

ELISA-enzyme-linked immunosorbent assay; APOE-apolipoprotein E; AD-Alzheimer's disease; MCI-mild cognitive impairment; H-healthy individuals; CN-cognitively normal subjects; aMCI-amnestic mild cognitive impairment; sMCI-stable mild cognitive impairment; preAD-preclinical Alzheimer's disease; prodAD-prodromal Alzheimer's disease

All above mentioned studies \[[@r52], [@r69], [@r72]\] have consistently found elevated CSF levels of YKL-40 in patients with AD and revealed a correlation between YKL-40 and markers of neurodegeneration, such as Tau and pTau~181~, even in preclinical stages of AD. This may give an assumption that neuroinflammation can emerge through a non-amyloid-related pathway. On the other hand, it is known that insoluble aggregates of Aβ may induce the inflammatory reactions and activation of microglia, resulting in production of proinflammatory mediators. Therefore, the relationship between YKL-40 and amyloid-related pathway in the development of AD was assessed in the paper of Alcolea *et al*. \[[@r72]\]. They divided cognitively normal patients according to Aβ~1-42~ levels, as above and below the cut-off point (550 pg/mL). The directionality of the correlation between YKL-40 and Aβ~1-42~ differed between participants: significant negative correlation was found in patients who had lower levels of Aβ~1-42~, whereas positive correlation between YKL-40 and Aβ~1-42~ was observed in patients with concentration of Aβ~1-42~ higher than 550 pg/mL \[[@r72]\]. This finding could explain some discrepancies found across studies concerning relationship of AD biomarkers with other biochemical CSF parameters, although mechanisms underlying this correlation in the absence of the pathologic process of AD require further investigation of amyloid deposition pathways, targeting not only basic AD biomarkers (Aβ~1-42~ and Aβ~1-42~ /Aβ~1-40~ ratio), but also amyloid precursor proteins or, perhaps, other isoforms of Aβ.

What is more, the connections between YKL-40 in CSF and amyloid pathology in cognitively healthy adults with increased risk for sporadic AD were recently assessed in the study of Racine *et al*. \[[@r73]\]. They hypothesized that CSF biomarkers of various pathological phenomena ongoing in the development of AD, such as amyloid plaques (lower  Aβ~1-42~), NFTs (elevated pTau~181~), axonal injury (increased Tau), and microglial activation/inflammation (high levels of YKL-40) should occur with larger amyloid deposition in neuroimaging at baseline and in longitudinal observation within 2 years. Indeed, in the initial assessment, Pittsburgh compound B (PiB) binding in AD-vulnerable regions was significantly associated with ratio of CSF YKL-40 to Aβ~1-42~ as well as other AD biomarkers to Aβ~1-42~. The authors indicated the possible use of YKL-40/Aβ~1-42~ ratio as a predictor of amyloid burden in PiB imaging at the baseline, although not in longitudinal observation \[[@r73]\].

The possible connection of CSF levels of YKL-40 with cortical atrophy, as a result of neuronal damage at early stage of AD, has been pointed out in another latest report from Alcolea *et al*. \[[@r74]\]. It seems that YKL-40 CSF concentrations may be linked to the AD pathology, especially to the cortical thickness (CTh) in some brain regions. In patients with amnestic MCI (aMCI), CSF levels of YKL-40 were not only increased when compared to cognitively normal subjects, but also significant negative correlations were found between CTh, especially in middle and inferior temporal areas,  and CSF levels of YKL-40, Tau, and pTau~181~ \[[@r74]\]. These observations were confirmed in subgroup of aMCI patients with low levels of Aβ~1-42~. Additionally, significant correlation between CSF levels of YKL-40 and concentrations of Tau and pTau~181~ but not Aβ~1-42~ has been demonstrated, similar to described previously results of Craig-Schapiro \[[@r52]\]. These findings suggest that YKL-40 CSF levels are related to the Tau-connected neurodegeneration \[[@r74]\].

Another interesting observation has been made by Gispert *et al*. \[[@r75]\], who revealed that CSF concentrations of YKL-40 and pTau~181~ in patients with early AD may be related to different cerebral morphometric patterns, such as gray matter (GM) volume. The authors evaluated connections between specific cerebral structures and CSF levels of YKL-40 across the early stages of AD, from normal through preclinical AD to mild dementia. They demonstrated that age-corrected YKL-40 levels were significantly increased in MCI patients in comparison with the rest of groups tested, *i.e*. normal controls and in subjects with preclinical AD or mild AD dementia patients. Moreover, no significant association was found with Aβ~1-42~, but a significant regression was found with pTau~181~ that was better modeled by a quadratic function. In patients with MCI due to AD and in AD group, referred to as "early AD", GM volume of certain cerebral structures was associated with age-corrected YKL-40 levels in inverse u-shaped nonlinear manner \[[@r75]\]. What is most interesting, CSF levels of YKL-40 related to a cerebral structures distinct from those affected with the progressive neurodegenerative atrophy associated with increasing CSF  p-tau values. This suggests that neuroinflammatory and neurodegenerative processes exist concurrently already at the early stages of cognitive impairment due to AD \[[@r75]\].

Determination of YKL-40 levels in CSF may be helpful not only in diagnosis of AD patient, but also in differentiation between various types of dementia. Olsson *et al*. \[[@r76]\] demonstrated that CSF levels of YKL-40 were significantly elevated in AD patients in comparison with cognitively healthy elderly controls. Additionally, a significant positive correlation was found between YKL-40 levels in CSF and Tau protein in AD patients. Interestingly, there were also higher concentrations of YKL-40 in CSF of MCI patients with an AD-indicative profile of biomarkers than in those with stable form of MCI. Moreover, concentrations of YKL-40 were increased in CSF of patients with MCI who progressed to vascular dementia (VaD) when compared to subjects with stable MCI within over 5-years observation period. It suggests diagnostic usefulness of CSF levels of YKL-40 in AD and for the distinction between stable phase of MCI and patients who progressed to VaD and AD \[[@r76]\].

6.. Role of YKL-40 in other neurological diseases
=================================================

YKL-40, as a biomarker of inflammation and activation of microglia within central nervous system, was also assessed in variety of neurological disorders occurring with neuroinflammatory process in reaction to pathological deposits, leading to neurodegeneration. Generally, NDs are characterized with similar changes on a subcellular level, including genetic mutations, atypical protein deposits and cell death \[[@r77], [@r78]\]. These atypical proteins include huntingtin, alpha-synuclein, tau protein, Aβ and many other proteins. Intracellular aggregation of misfolded toxic proteins and products of their degradation in cell structures are the histopathological changes seen not only in AD, but also observed in Huntington's (HD), and Parkinson's diseases (PD), amyotrophic lateral sclerosis (ALS) and dementia with Lewy bodies (DLB).

Increased concentrations of YKL-40 in CSF were observed in HD, which is a neurodegenerative disorder caused by a mutation in *huntingtin* gene (also called *HD*), where excessive (more than 36) repeats in codon CAG (cytosine-adenine-guanine) result in formation of an unstable, mutated Huntingtin protein (mHtt). HD affects muscle coordination and leads to mental decline as well. Moreover, neuroinflammation in HD is a well-known process, which is probably an early event in the pathology of this disease. In development of HD, the activation of immune system in brain tissue may occur even 15 years before onset of symptomatic disease \[[@r79]\]. CSF levels of YKL-40 were 17% higher in full-symptomatic carriers of *HD* gene in comparison with premanifest *HD* gene-expansion carriers and 18% higher than in control group, whereas no difference between presymptomatic *HD* gene carriers and healthy subjects was found \[[@r80]\]. It has not been elucidated whether YKL-40, a marker for glia activation, plays a direct role in the pathology of HD, although their results are in line with earlier studies on increased glia activation \[[@r79]\]. It suggests that YKL-40 might play a role in pathology of HD, although it remains unclear whether elevated YKL-40 is a part of the disease-specific pathology, nonspecific response to inflammation or ongoing neuro- degeneration processes.

PD is a long term disorder of the central nervous system that affects the motor neuron system and cognitive functioning. Pathological changes include accumulation of alpha-synuclein, which results in forming insoluble fibrils, a primary structural component of Lewy bodies in neuronal tissue \[[@r81]\]. Therefore, PD is described as synucleinopathy \[[@r82], [@r83]\]. Atypical parkinsonian disorders (P+ diseases), such as progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA) are also connected with pathological protein deposits in the brain. These P+ diseases currently are divided to synucleinopathies (DLB, MSA) or tauopathies (PSP, CBD), concerned with pathological tau deposits. CSF concentrations of YKL-40 were assessed in subjects suffering from PD and in patients with various P+ diseases \[[@r84]\]. Interestingly, YKL-40  was significantly lower in patients with PD and P+ than in healthy controls. Moreover, YKL-40 levels were decreased in patients with synucleinopathies when compared to tauopathies, what suggests that glial activation is reduced in the brains of PD patients and other synucleinopathies in comparison with patients who have tauopathies or healthy controls \[[@r84]\].

As it was stated above, neuroinflammation is connected with cognitive impairment. Therefore, YKL-40 was also pointed out as a possible biomarker in other neurological diseases ongoing with cognitive decline. Bipolar disorder (BD) is one of such diseases, where cognitive loss is a common symptom and a key predictor of patients' functioning. On the other hand, it was indicated that chronic neuroinflammation may be present in BD \[[@r85]\]. Increased levels of microglia markers in frontal cortex were found in post-mortem examination of patients with BD \[[@r86]\], what suggests that microglia play a role in the pathophysiology of this disease. Moreover, elevated CSF levels of YKL-40 were found in euthymic patients with BD in comparison with healthy controls, independent on age, gender, smoking status, body mass index, functioning of blood-brain barrier, and acute-phase serum proteins \[[@r87]\]. In the study of Rolstad *et al*., CSF levels of YKL-40 were also assessed in mood-stabilized patients with various types of BD associated with cognitive impairment \[[@r88]\]. The linear regression analysis revealed that YKL-40 significantly accounted for the variance in executive functioning, but not in cognitively healthy control subjects, what confirms the hypothesis that inflammatory processes within brain tissue are involved in the pathophysiology of BD \[[@r88]\].

Since YKL-40 is up-regulated in a variety of inflammatory conditions, this protein was also assessed in multiple sclerosis (MS), which is also characterized with inflammatory response \[[@r67]\]. It was shown that expression of YKL-40 was mainly associated with reactive astrocytes and was more pronounced in regions of inflammatory cells in MS \[[@r89]\]. Moreover, significant elevation of YKL-40 concentrations was observed in the CSF of MS patients  \[[@r89]\]. When evaluated during various phases of MS, the concentrations of YKL-40 in CSF were increased during relapse, remission and secondary progression phase when compared with healthy subjects \[[@r90]\]. Additionally, CSF levels of this protein decreased after immunosuppressive treatment of MS patients \[[@r90]\], what suggests possible use of YKL-40 as a pharmacodynamic marker in this disease.

7.. Possibility of therapeutic strategies targeting neuroinflammation and YKL-40 in AD
======================================================================================

Up to this point, there are no efficient and accessible treatments to prevent the beginning and/or the progression of AD \[[@r6], [@r8]\]. Although for the last twenty years a lot of attempts have been done to establish an effective disease-modifying treatment and to delay the development of AD, they are still insufficient. Most of AD medications used are nootropic, procognitive drugs, that could to some extent improve the cognition and memory in dementia affected patients. These drugs belong to different groups, including agonists of N-methyl-D-aspartate (NDMA) receptor, reversible inhibitors of cholinesterase, cerebral blood flow improving treatment and psychotropic drugs. Agonists of NMDA receptor, such as memantine, exhibit a protective effect on the neuronal cells and also enhance the cognition in AD \[[@r91]\]. Reversible inhibitors of acetylcholinesterase (AChE), for instance donepezil or rivastigmine, can improve memory and stabilize patient's behavior \[[@r92]\]. The drugs used to improve cerebral blood flow can also influence the brain nutrition and its functioning, which may have a positive impact on mental processes and daily activity. Additionally, a supplementation of antioxidants such as vitamin C, E, and coenzyme Q it also recommended. Unfortunately, no new drugs have been licensed for AD since memantine in 2002.

The hypothesis that neuroinflammation is closely linked with a variety of neurodegenerative diseases, including AD, implies the probability that novel anti-inflammatory therapies could reverse the consequences of neurodegeneration. Therefore, the use of non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids is expected to decrease the risk of developing the disease.

NSAIDs act by blocking the conversion of prostaglandin H2 into other prostaglandins (PGs) and thromboxane (TX). By inhibition of cyclooxygenase activity, NSAIDs could block inflammation underlying AD pathogenesis at early stages. The positive influence of indometacin administration on the results of psychometric tests and AD assessment scale was shown in several studies \[[@r93], [@r94]\]. Moreover, naproxen sodium application could also result in AD patients outcome, leading to reduced ratio of CSF tau to Aβ~1-42~ \[[@r95]\]. Unfortunately, no apparent effects of new generation NSAIDs, such as selective cyclooxygenase-2 inhibitors or nimesulide on AD were observed in clinical trials \[[@r40]\].

Moreover, the effect of various systemic comorbidities, including diabetes and hypertension as well as systemic inflammation could be considered as possible targets of AD therapy in future studies. Despite known anti-inflammatory action of statins, the clinical trials with these drugs (simvastatin and atorvastatin) gave no positive effects on CSF levels of Aβ isoforms \[[@r96]\] or neuropsychological tests results \[[@r97], [@r98]\], respectively.

In addition, aerobic exercise has been shown to decrease the proliferation of microglia in the brain and hippocampal expression of immune-related genes, as well as to reduce the expression of inflammatory cytokines such as TNF-α. Therefore physical exercise could be considered as the preventing factor and supplementary treatment for various neuroinflammatory diseases, including AD \[[@r99]\]. An interesting study on this field, concerning strategies for cognitive wellness promotion, including nutritional guidance, physical exercise, cognitive training, and social intervention was The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). The researchers concluded that these developing interventions are needed as soon as possible (even before the onset of the disease clinical manifestation), since it might improve patients' cognitive functions and prevent or delay dementia symptoms \[[@r100]\].

Although the biophysiological activity of YKL-40 is poorly understood, this protein is believed to be involved not only in AD development and progression, but also to be associated with proliferation of connective tissue cells \[[@r101], [@r102]\] and activation of vascular endothelial cells \[[@r103]\]. Furthermore, the elevation of YKL-40 serum levels in a variety of chronic inflammatory diseases \[[@r104], [@r105]\] suggests the relationship of this protein with the process of extra- cellular matrix remodeling \[[@r58], [@r106]\]. Within last few years, the pathologic role of YKL-40 in development of a broad type of human cancers has been highlighted. Moreover, increasing evidence has indicated the particular role of YKL-40 as an angiogenic factor in cancer development. The study of Faibish *et al*. demonstrated blockade of angiogenesis and progression using YKL-40 neutralizing monoclonal antibodies (mAY) \[[@r107]\]. Therefore, the potential utility of mAY could implicate its potential therapeutic value in cancers. Taking these findings into account, it seems reasonable to focus on inhibiting the YKL-40 function by using mAY as potential therapeutic target in AD and other neurodegenerative conditions.

Conclusion
==========

This review summarizes recent data regarding a suggested role of YKL-40 as a candidate inflammatory biomarker of AD. It is already known that neuroinflammation plays an important role in AD pathology. The latest studies have pointed out the elevated CSF levels of YKL-40 in neuro- degenerative disorders, especially in AD. The correlations between CSF concentrations of YKL-40 and classical AD biomarkers, such as Tau protein and its phosphorylated form (pTau~181~) have been found. Moreover, it has been demonstrated that YKL-40 might be useful in the diagnosis and prognosis of the AD progression. Additionally, YKL-40 might be associated in the pathophysiology of other neuro- degenerative diseases ongoing with inflammatory background, such as Huntington's disease as well as Parkinson's disease. Furthermore, the interactions between neuroinflammation and neurodegenerative diseases, especially AD, might represent a possible hypothetic target for novel AD drugs, modulating YKL-40 activity, although this issue requires further investigation.
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###### 

A comparison of YKL-40 concentrations in CSF (all using ELISA method).

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Refs.**                                                                                    **Group Tested**    **Concentration**\                                                                      
                                                                                                                   **(Median\*/mean\*\*) \[ng/mL\]**                                                       
  -------------------------------------------------------------------------------------------- ------------------- --------------------------------------------------------------------------------------- -------------------
  Rosén *et al*.; 2014 \[[@r60]\]                                                              25 AD               199.211 \*                                                                              

  25 H                                                                                         112.631 \*                                                                                                  

  Antonell *et al*.; 2014 \[[@r61]\]                                                           18 preAD            330.0 \*\*                                                                              

  22 prodAD                                                                                    364.1 \*\*                                                                                                  

  43 H                                                                                         260.5 \*\*                                                                                                  

  Kester *et al*.; 2015 \[[@r62]\]                                                             65 AD               288.0 \*\*                                                                              

  61 MCI                                                                                       304.0 \*\*                                                                                                  

  37 H                                                                                         231.0 \*\*                                                                                                  

  Sutphen *et al*.; 2015 \[[@r63]\]                                                            169 H               61 APOE ε4 carriers (early age: 45-54 yrs; mid age: 55-64 yrs; late age: 65-74 yrs):\   early: 188.4 \*\*
                                                                                                                   19 early (2 with genotype ε2/ε4, 14 with genotype ε3/ε4, 3 with ε4/ε4)\                 
                                                                                                                   17 mid (2 with genotype ε2/ε4, 12 with genotype ε3/ε4, 3 with ε4/ε4)\                   
                                                                                                                   25 late (2 with genotype ε2/ε4, 20 with genotype ε3/ε4, 3 with ε4/ε4)                   

  mid: 240.6 \*\*                                                                                                                                                                                          

  late: 281.5 \*\*                                                                                                                                                                                         

  108 APOE ε4 non-carriers (early age: 45-54 yrs; mid age: 55-64 yrs; late age: 65-74 yrs):\   early: 180.3 \*\*                                                                                           
  26 early (3 with genotype ε2/ε3, 23 with ε3/ε3)\                                                                                                                                                         
  44 mid (1 with genotype ε2/ε2, 8 with genotype ε2/ε3, 35 with ε3/ε3)\                                                                                                                                    
  38 late (1 with genotype ε2/ε2, 6 with genotype ε2/ε3, 31 with ε3/ε3)                                                                                                                                    

  mid: 231.3 \*\*                                                                                                                                                                                          

  late: 301.1 \*\*                                                                                                                                                                                         

  Alcolea *et al*.; 2015 \[[@r64]\]                                                            27 aMCI             247.07 \*\*                                                                             

  80 CN                                                                                        200.37 \*\*                                                                                                 

  Racine *et al*.; 2016 \[[@r65]\]                                                             108 AD              139.47 \*\*                                                                             

  Alcolea *et al*.; 2015 \[[@r66]\]                                                            266 H               196.77 \*                                                                               

  Gispert *et al*.; 2016 \[[@r75]\]                                                            15 AD               333.47 \*\*                                                                             

  28 MCI due to AD                                                                             427.71 \*\*                                                                                                 

  20 preAD                                                                                     320.57 \*\*                                                                                                 

  53 H                                                                                         283.86 \*\*                                                                                                 

  Olsson *et al*.; 2013 \[[@r67]\]                                                             96 AD               241.582 \*\*                                                                            

  81 sMCI                                                                                      171.687 \*\*                                                                                                

  65 H                                                                                         194.622 \*\*                                                                                                

  Bonneh-Barkay *et al*.; 2010 \[[@r81]\]                                                      10 AD               212.0 \*                                                                                

  12 H at younger age (\<40 yrs)                                                               109.0 \*                                                                                                    

  7 H at older age (60-70 yrs)                                                                 218.0 \*                                                                                                    
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
